A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma

Clinical trial NCT00502307 · COMPLETED

Trial details

NCT number: NCT00502307
Sponsor: AVEO Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Renal Cell

Start date: 2007-10-01
Primary completion: 2010-08-01
Enrollment: 272

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.